The goal of this clinical trial is to find out whether non-ablative radiofrequency (RF) applied together with pelvic-floor muscle exercises can ease vaginal dryness and other symptoms of genitourinary syndrome of menopause (GSM) in women aged 18-75 years who have survived breast cancer and currently experience those symptoms. The main questions it aims to answer are: Does the combination of RF + exercise lower the 0-to-10 vaginal-dryness score more than sham (inactive) RF + exercise at 6 weeks (end of treatment) and 3 months? What other changes (pain during intercourse, Vaginal Health Index, urinary and sexual function, pelvic-floor strength, overall satisfaction) are seen in each group? Researchers will compare six sessions of active RF with six sessions of sham (inactive) RF to see whether the active treatment works better. Participants will: Visit the hospital once a week for 6 weeks. Each visit includes about 20 minutes of intra-/extra-vaginal RF (or sham) and 20 minutes of guided pelvic-floor training whose content is adapted and progressed throughout the study. Carry out a structured, progressive home-exercise programme, recording any discomfort in a diary. Complete questionnaires and tests at baseline, after session 6, and 3 months later.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
Non-ablative radiofrequency is applied using a Capenergy C500 device at a target tissue temperature of ≤ 45 °C, once a week for 6 consecutive weeks. Treatment is delivered through two channels simultaneously: a capacitive plate placed on the suprapubic area and an intracavitary vaginal probe. Each session lasts 20 minutes and is followed by 20 minutes of pelvic-floor muscle training guided by biofeedback. Participants will also follow a progressive home exercise programme and record adherence and events. In addition, all participants will receive education on pelvic-floor anatomy and function, underlying mechanisms of pain after breast cancer, bladder and bowel retraining, respiratory pattern re-education, and-if interested-information on sexual health.
Participants will receive one session per week for 6 weeks of sham (placebo) radiofrequency using the Capenergy C500 in Placebo Mode (no temperature increase), designed to simulate active treatment. The screen will display a simulated "delivered energy" value; temperature and energy readings will be hidden; LED indicators will activate sequentially; and a suprapubic capacitive plate and intracavitary probe will be used with the same protocol as in the intervention group. This will be followed by 20 minutes of pelvic-floor muscle training guided by biofeedback, identical to the intervention group. Participants will also follow a progressive home exercise programme and record adherence and events. All participants will receive education on pelvic-floor function, pain mechanisms after breast cancer, bladder/bowel retraining, breathing pattern correction, and-if interested-sexual health.
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain
RECRUITINGSubjective sensation of vaginal dryness
Measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no dryness" and 10 indicates "maximum dryness". The NRS is a self-reported, single-item scale commonly used for subjective symptom intensity.
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Subjective sensation of pain during sexual activity (NRS 0-10)
Measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no pain" and 10 indicates "maximum pain during sexual activity". The NRS is a self-reported, single-item scale commonly used for subjective symptom intensity.
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Subjective sensation of vaginal itching (NRS 0-10)
Measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no itching" and 10 indicates "maximum itching". The NRS is a self-reported, single-item scale commonly used for subjective symptom intensity.
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Vaginal Health Index Score
The Vaginal Health Index Score assesses five parameters (elasticity, secretions, epithelial integrity, moisture, and pH), each rated from 1 to 5. The total score ranges from 5 (worst condition) to 25 (optimal vaginal health).
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Female Sexual Function Index total score
The FSFI is a 19-item self-reported questionnaire evaluating six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores range from 2 to 36. A score below 26.55 is considered indicative of sexual dysfunction based on established clinical cutoffs.
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Vaginal pH level
The pH will be quantified using MColorpHast™ pH indicator strips (0-14 range, Merck®). The strip will be placed directly on the right lateral vaginal wall for a few seconds, and the result will be determined by comparing the colour to the manufacturer's reference scale. Higher pH values are typically associated with hypoestrogenic states and genitourinary symptoms of menopause
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Pelvic organ support parameters measured by POP-Q system
Pelvic anatomy will be assessed using the Pelvic Organ Prolapse Quantification (POP-Q) system, with the patient in gynecological position and using a speculum. The following parameters will be recorded: genital hiatus (GH), perineal body (PB), total vaginal length (TVL), and reference points Aa, Ba, C, D, Ap, and Bp.
Time frame: T0 (baseline, before intervention); T2 (3 months after T1)
International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF total score)
The ICIQ-SF is a self-reported questionnaire assessing the frequency, severity, and impact of urinary incontinence. Scores range from 0 to 21, with higher scores indicating greater severity.
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
ICIQ-FLUTS
The ICIQ-FLUTS (International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms) is a self-administered questionnaire designed to evaluate female lower urinary tract symptoms (LUTS) and their impact on quality of life. It consists of 12 items grouped into three independent domains: storage symptoms, voiding symptoms, and incontinence symptoms. Each item assesses the presence and perceived severity of the symptom
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Pelvic-floor muscle strength (Modified Oxford Scale, 0-5)
Assessed by vaginal palpation using the Modified Oxford Scale, which rates voluntary pelvic-floor muscle contraction from 0 (no contraction) to 5 (strong contraction). This is a validated, clinician-administered tool.
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Pelvic-floor muscle activity measured by surface electromyography (μV)
Pelvic-floor muscle activation is measured using surface electromyography (sEMG) with an intracavitary Periform® vaginal probe. The outcome is expressed in microvolts (μV) and reflects the neuromuscular response of the pelvic floor during both contraction and resting phases. For each participant, the final value will be calculated as the mean of three voluntary contractions, with 10-second rest intervals between contractions
Time frame: T0 (baseline, before intervention); T1 (immediately after completing the intervention); T2 (3 months after T1)
Subjective global impression of improvement (7-point Likert scale)
Participants will be asked to rate their overall perception of improvement in symptoms after the intervention using a 7-point Likert scale, specifically designed for this study and based on the Patient Global Impression of Change (PGIC). The scale ranges from 1 ("very much improved") to 7 ("very much worse"), reflecting the participant's subjective global impression of improvement compared to their baseline condition.
Time frame: T1 (immediately after completing the intervention); T2 (3 months after T1)
Incidence of adverse events related to the intervention
Any unexpected or undesired sign, symptom, or condition temporally associated with the intervention will be recorded
Time frame: T1 (immediately after completing the intervention); T2 (3 months after T1)
Adherence to prescribed home pelvic-floor training
Measured through a self-reported diary where participants record the frequency and completion of home-based pelvic-floor exercises. Adherence is expressed as a percentage of the total prescribed sessions completed.
Time frame: T1 (immediately after completing the intervention); T2 (3 months after T1)
Local recurrence of breast cancer at 12 months
Oncological follow-up will document any confirmed local breast cancer recurrence occurring within 12 months of completing the intervention.
Time frame: 12 months after T1
Participant's belief regarding group allocation (intervention vs. placebo)
At the end of the intervention, participants will be asked whether they believe they received the active treatment or the placebo treatment.
Time frame: T1 (immediately after completing the intervention)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.